A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Inclusion Criteria

• •Has a confirmed diagnosis of solid tumor for one of the following types of cancer: previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, or platinum-resistant ovarian cancer.
• •Has metastatic disease that has progressed during or following previous treatment appropriate for the disease type
• •Presence of radiographically measurable disease.
• •Is willing to provide tumor tissue
• •Has adequate organ function
• •Has a negative test or adequate therapy for human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C.
• •Has completed all prior therapy.
• •Female subjects of childbearing potential must have a negative serum pregnancy test.
• •Both male and female subjects must be willing to use adequate contraception.